Actos Lawsuit

The FDA released a warning of safety on June 15th, 2011 regarding a conncetion between Actos (used to treat type 2 diabetes) and bladder cancer.

The agency released a warning based on a five year analysis of an on going study being done by Takeda Pharmaceuticals, the manufacturers of Actos. The study found no increased risk of bladder cancer in new users, but patients with the longest exposure had a significantly larger chance of contracting bladder cancer. By the numbers, people taking this drug for more than a year were 40% more at risk than new or non-users. Also, due to these results, moving forward, Actos will be forced to include bladder cancer as a side effect on the label.

The FDA has also advised users to be aware of the warning signs of Actos bladder cancer, which include:

  • Urgent need to urinate
  • Blood in urine
  • Pain during urination
  • Back or lower abdominal pain

The FDA has also brought attention to the possibility of a link between Actos and Rhabdomyolysis (deterioration of muscle tissue). Rhabdomyolysis is characterized by muscle aches, pains and weakness and can also result eventually in kidney failure.

Symptoms of this side effect include:

▪ muscle weakness

▪ fever

▪ fatigue

▪ muscle pain

▪ nausea

▪ vomiting

▪ dark colored urine

These symptoms can also be confused with a list of other ailments; report them to your doctor immediately.

It has been alleged that drug maker, Takeda Pharmaceutical, failed to provide proper warnings, causing them to not effectively communicate the risks associated with its diabetes drug.

Many patients have already come together against Takeda Pharmaceuticals, many of them already diagnosed with bladder cancer allegedly in response to their repeated dosages of Actos. Thousands of Actos lawsuits began the filing process in early August to hold Takeda Pharmaceuticals responsible for the issues caused to their patients by their blatant negligence in this case.

These Actos lawsuit claims are time limited, so don’t hesitate to begin the process.

Leave a Reply